These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10624455)

  • 1. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.
    Bravenboer N; Papapoulos SE; Holzmann P; Hamdy NA; Netelenbos JC; Lips P
    Osteoporos Int; 1999; 9(6):489-93. PubMed ID: 10624455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
    Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
    J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
    Chavassieux PM; Arlot ME; Reda C; Wei L; Yates AJ; Meunier PJ
    J Clin Invest; 1997 Sep; 100(6):1475-80. PubMed ID: 9294113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension.
    Brumsen C; Papapoulos SE; Lips P; Geelhoed-Duijvestijn PH; Hamdy NA; Landman JO; McCloskey EV; Netelenbos JC; Pauwels EK; Roos JC; Valentijn RM; Zwinderman AH
    J Bone Miner Res; 2002 Jun; 17(6):1057-64. PubMed ID: 12054161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
    Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I
    Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
    Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
    J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation.
    Thomas T; Barou O; Vico L; Alexandre C; Lafage-Proust MH
    J Bone Miner Res; 1999 Feb; 14(2):198-205. PubMed ID: 9933473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
    Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
    Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: a 1-year, double-blind, randomized, placebo-controlled study.
    Brixen K; Hansen TB; Hauge E; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C; Melsen F
    J Bone Miner Res; 2000 Feb; 15(2):293-300. PubMed ID: 10703931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL; Fornasier TL; Bogoch TR
    J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
    Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tiludronate on bone loss in paraplegic patients.
    Chappard D; Minaire P; Privat C; Berard E; Mendoza-Sarmiento J; Tournebise H; Basle MF; Audran M; Rebel A; Picot C
    J Bone Miner Res; 1995 Jan; 10(1):112-8. PubMed ID: 7747617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy.
    Kim SH; Lim SK; Hahn JS
    Am J Med; 2004 Apr; 116(8):524-8. PubMed ID: 15063813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
    Kuntz D; Marie P; Berhel M; Caulin F
    Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
    Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
    J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study.
    Vedi S; Ninkovic M; Garrahan NJ; Alexander GJ; Compston JE
    Transpl Int; 2002 Jun; 15(6):290-5. PubMed ID: 12072899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects.
    Lundy MW; Stauffer M; Wergedal JE; Baylink DJ; Featherstone JD; Hodgson SF; Riggs BL
    Osteoporos Int; 1995 Mar; 5(2):115-29. PubMed ID: 7599448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
    Aris RM; Lester GE; Renner JB; Winders A; Denene Blackwood A; Lark RK; Ontjes DA
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):941-6. PubMed ID: 10988110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.